NCI’s Message and High Priorities

Might 4, 2026,
by Anthony Letai, M.D., Ph.D.

I’ve attended the AACR Annual Assembly many occasions, however doing so within the capability of NCI Director final week was an honor I by no means imagined. I appreciated the nice and cozy welcome in San Diego from AACR and the various constructive interactions with a neighborhood that’s really unmatched in science.

The complete chain of most cancers analysis was there—from early-stage investigators new to their careers, to fundamental scientists finding out how most cancers works, clinicians testing new therapies, trade companions scaling them, and advocates reminding us why this work issues. And that chain is important, as a result of breakthroughs occur solely by means of collaboration, constructed step-by-step on the progress of the work of scientists who laid the groundwork lengthy earlier than.

I used to be impressed not solely by the formal shows but in addition by the conversations that unfolded between workshops and periods, at poster periods, and on the NCI exhibit sales space. AACR as soon as once more confirmed how these exchanges create momentum and lay the muse for actual progress.

Science that stood out at AACR

A number of analysis areas drew important consideration and can proceed to form our work transferring ahead:

• Immuno-oncology. We’ve seen significant success with immune checkpoint inhibitors and mobile therapies, however necessary questions stay. Throughout periods, I noticed a continued give attention to why some folks with most cancers reply to those therapies whereas others don’t, and the best way to translate these insights right into a extra constant profit. A few of this entails the kind of thrilling new concepts we have to check extra quickly in human research. These discussions are removed from settled, however they’re transferring in a productive course.
• Most cancers therapeutic vaccines. Most cancers vaccine analysis is gaining momentum, and AACR supplied a beneficial alternative to focus on how NCI is advancing this subject based mostly on early analysis that implies vaccines may assist stop recurrence, notably in cancers the place relapse is widespread. The query now could be the best way to check these vaccines rigorously and at scale. NCI’s partnership with the Basis for the Nationwide Institutes of Well being will try this. Later this yr, we’re focused to unveil a plan to conduct a number of well-structured trials that may assist us quickly and decisively uncover probably the most promising therapeutic vaccine avenues to pursue.
• Useful precision drugs. The thought is easy: if you wish to know whether or not a drug will work, check it straight on an individual’s tumor cells. In an overflowing session, work offered at AACR confirmed that new applied sciences and knowledge more and more help this method. The subsequent step is determining how to make sure these approaches are dependable and might be extensively utilized in on a regular basis analysis and care settings. That’s why we’re convening the neighborhood—first by means of a workshop this summer season—to outline how NCI can bolster progress in purposeful precision drugs.
• Synthetic intelligence. As anticipated, AI was a spotlight of a number of periods, highlighting this know-how and its vary of makes use of in most cancers analysis. AI is right here. I imagine the problem now isn’t just growing instruments however enabling the analysis neighborhood to work collectively—so we are able to construct helpful instruments quicker and guarantee they work throughout methods. I would like NCI to assist foster an surroundings the place AI options are shared and interoperable.

Priorities transferring ahead

AACR additionally bolstered a number of priorities that stay central to NCI’s work.

One is the necessity to enhance the effectivity of medical trials—particularly early-phase trials. Proper now, too many obstacles decelerate the trail from a promising concept to testing it in people. Different international locations transfer quicker, and we have to study from them whereas sustaining our requirements. These efforts had been properly obtained at AACR, and NCI seems ahead to serving to velocity the trail to first-in-human trials.

We additionally stay targeted on prevention and entry. Higher most cancers therapies have restricted impression if folks can’t entry care, and discoveries offered at AACR jogged my memory how advances typically outpace our skill to ship them equitably. We’re main an effort involving the main U.S. well being businesses referred to as the Prevention, Screening, and Early Detection Initiative, or PSEDI, to reinforce entry to well being screening and care, beginning within the nation’s underserved areas. This venture, nonetheless in early planning, goals to broaden entry to evidence-based well being prevention and screening methods from a pilot part of a number of U.S. counties to wider attain throughout the nation.

One other space of emphasis is on the significance of use of human-based fashions in most cancers analysis, which I mentioned in my keynote handle at AACR. Animal fashions have taught us an incredible quantity, and so they to proceed to play a important function in most cancers analysis. However fashionable applied sciences allow us to extra straight research human tumors. We should always take full benefit of those approaches. They may also help us make smarter choices earlier about what’s price pursuing.

Your NCI

Lastly, AACR supplied a becoming backdrop to introduce an initiative NCI is launching to assist educate the general public about how taxpayer {dollars} result in actual most cancers breakthroughs: Your NCI.

I unveiled a video on the AACR opening ceremony that traced the invention of checkpoint inhibitors—that spawned immunotherapy—from one NCI grant awarded about 4 many years in the past to as we speak. Now, the primary drug utilizing checkpoints, pembrolizumab, is a extremely efficient remedy for 43 cancers. 

This video received an awesome reception. Search for extra on the Your NCI initiative this summer season. 

For those who’re doing analysis, when you’re collaborating in a most cancers medical trial, when you’re serving to ship a remedy—you’re a part of NCI. At AACR, we noticed the complete system, the place concepts are examined, challenged, refined, and translated into higher outcomes for folks with most cancers. I stay up for collaborating with you.